1-19 of 19
Mario Sznol
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1167: Prospective analysis of pretreatment circulating CD4 memory T cell features associated with severe immunotherapy toxicity

Abul Usmani, Noah Earland, Wubing Zhang, Peter K. Harris, Antonietta Bacchiocchi, Chloe M. Sachs, Aishwarya Nene, David Y. Chen, Mario Sznol, Ruth Halaban, Aaron M. Newman, Aadel A. Chaudhuri
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1167.
https://doi.org/10.1158/1538-7445.AM2024-1167
Published: 22 March 2024
View article titled, Abstract 1167: Prospective analysis of pretreatment circulating CD4 memory T cell features associated with severe immunotherapy toxicity
Journal Articles

Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors

Jason J. Luke, Melissa Johnson, Anthony Tolcher, Christopher T. Chen, Tong Dai, Brendan D. Curti, Anthony El-Khoueiry, Mario Sznol, Brian S. Henick, Christine Horak, Pushpa Jayaraman, Christopher B. Cole, Dawn Wilson, Lizhi Cao, Li Peng, David Feltquate, Deanne Lathers, Manish R. Sharma
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT034.
https://doi.org/10.1158/1538-7445.AM2023-CT034
Published: 14 April 2023
View article titled, Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors
Journal Articles

Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better

Dijana Djureinovic, Sarah A. Weiss, Irina Krykbaeva, Rihao Qu, Ioannis Vathiotis, Myrto Moutafi, Lin Zhang, Ana L. Perdigoto, Wei Wei, Gail Anderson, William Damsky, Michael Hurwitz, Barbara Johnson, Amit Mahajan, Frank Hsu, Kathryn Miller-Jensen, Yuval Kluger, Mario Sznol, Susan M. Kaech, Marcus Bosenberg, Lucia Jilaveanu, Harriet M. Kluger
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3287.
https://doi.org/10.1158/1538-7445.AM2023-3287
Published: 04 April 2023
View article titled, Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
Journal Articles

Abstract 6670: Association between circulating CD4 memory T cell levels and severe immune-related adverse events in melanoma patients treated with immune checkpoint blockade

Abul Usmani, Noah Earland, Wubing Zhang, Peter K. Harris, Antonietta Bacchiocchi, Aishwarya Nene, David Y. Chen, Mario Sznol, Ruth Halaban, Aaron M. Newman, Aadel A. Chaudhuri
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6670.
https://doi.org/10.1158/1538-7445.AM2023-6670
Published: 04 April 2023
View article titled, Abstract 6670: Association between circulating CD4 memory T cell levels and severe immune-related adverse events in melanoma patients treated with immune checkpoint blockade
Journal Articles

Abstract 1179: Rational combinations with the dual RAF/MEK inhibitor VS-6766 for treatment of cutaneous melanoma harboring BRAF, NRAS, NF1 or CRAF mutations

Antonella Bacchiocchi, Silvia Coma, Sanjib Chowdhury, Mario Sznol, Ruth Halaban, Jonathan A. Pachter
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1179.
https://doi.org/10.1158/1538-7445.AM2022-1179
Published: 15 June 2022
View article titled, Abstract 1179: Rational combinations with the dual RAF/MEK inhibitor VS-6766 for treatment of cutaneous melanoma harboring BRAF, NRAS, NF1 or CRAF mutations
Journal Articles

Abstract CT041: Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)

Michael Millward, Justin C. Moser, Diwakar Davar, Mark Voskoboynik, Nehal J. Lakhani, Rachel E. Sanborn, Jaspreet Grewal, Ajita Narayan, Mario Sznol, Keren Schieber, Hany Zayed, Christine Dela Cruz, Graciela Perez, Stanford L. Peng
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT041.
https://doi.org/10.1158/1538-7445.AM2022-CT041
Published: 15 June 2022
View article titled, Abstract CT041: Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1)
Journal Articles

Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial

F. Stephen Hodi, Harriet Kluger, Mario Sznol, Richard Carvajal, Donald Lawrence, Michael Atkins, John Powderly, William Sharfman, Igor Puzanov, David Smith, Philip Leming, Evan Lipson, Janis Taube, Robert Anders, Christine Horak, Joel Jiang, David McDermott, Jeffrey Sosman, Julie Brahmer, Drew Pardoll, Suzanne Topalian
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT001.
https://doi.org/10.1158/1538-7445.AM2016-CT001
Published: 15 July 2016
View article titled, Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
Journal Articles

Abstract 1306: Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC)

Toni K. Choueiri, Mayer N. Fishman, Bernard Escudier, Walter M. Stadler, Scott Chasalow, Petra Ross-Macdonald, Maria Jure-Kunkel, Mario Sznol, Jason S. Simon
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1306.
https://doi.org/10.1158/1538-7445.AM2015-1306
Published: 01 August 2015
View article titled, Abstract 1306: Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC)
Journal Articles

Abstract CT106: A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma

Mark R. Middleton, Pippa Corrie, Mario Sznol, Jeffrey Infante, Clive Mulatero, Jeff Evans, Neil Steven, David Krige, William H. Shingler, Yvonne McGrath, Namir J. Hassan, Bent K. Jakobsen
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): CT106.
https://doi.org/10.1158/1538-7445.AM2015-CT106
Published: 01 August 2015
View article titled, Abstract CT106: A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma
Journal Articles

Abstract PR05: Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo

Rituparna Das, Rakesh Verma, Mario Sznol, Chadra Sekhar Boddupalli, Scott Gettinger, Harriet Kluger, Madhav Dhodapkar, Kavita Dhodapkar
Journal: Cancer Research
Cancer Res (2015) 75 (14_Supplement): PR05.
https://doi.org/10.1158/1538-7445.MEL2014-PR05
Published: 16 July 2015
View article titled, Abstract PR05: Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo
Journal Articles

Role of Chitinase 3–like-1 and Semaphorin 7a in Pulmonary Melanoma Metastasis

Bing Ma, Erica L. Herzog, Chun Geun Lee, Xueyan Peng, Chang-Min Lee, Xiaosong Chen, Sara Rockwell, Ja Seok Koo, Harriet Kluger, Roy S. Herbst, Mario Sznol, Jack A. Elias
Journal: Cancer Research
Cancer Res (2015) 75 (3): 487–496.
https://doi.org/10.1158/0008-5472.CAN-13-3339
Published: 01 February 2015
View article titled, Role of Chitinase 3–like-1 and Semaphorin 7a in Pulmonary Melanoma Metastasis
Open the PDF for Role of Chitinase 3–like-1 and Semaphorin 7a in Pulmonary Melanoma Metastasis in another window
Includes: Supplementary data
Journal Articles

Abstract CT329: A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma

Mark Middleton, Jeff Evans, Neil Steven, Pippa Corrie, Clive Mulatero, Mario Sznol, William H. Shingler, Dominic Smethurst, Namir Hassan, Yvonne McGrath, Bent Jakobsen
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): CT329.
https://doi.org/10.1158/1538-7445.AM2014-CT329
Published: 01 October 2014
View article titled, Abstract CT329: A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma
Journal Articles

Abstract 1477: Tumor cell-leukocyte fusion in human cancer: A melanoma brain metastasis with a donor-patient hybrid genome following allogeneic BMT

Rossitza Lazova, Greggory S. Laberge, Eric Duvall, Nicole Spoelstra, Mario Sznol, Dennis Cooper, Richard Spritz, John M. Pawelek
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 1477.
https://doi.org/10.1158/1538-7445.AM2011-1477
Published: 15 April 2011
View article titled, Abstract 1477: Tumor cell-leukocyte fusion in human cancer: A melanoma brain metastasis with a donor-patient hybrid genome following allogeneic BMT
Journal Articles

Abstract #2409: Antitumor activity and immune cell subset analysis of anti-CTLA-4 antibodies in transgenic mice expressing the dominant negative TGF\#946;-RII (DNR) gene in CD4+ and CD8+ cells

Stephen Wrzesinski, Mario Sznol, Richard Flavell
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 2409.
Published: 01 May 2009
View article titled, Abstract #2409: Antitumor activity and immune cell subset analysis of anti-CTLA-4 antibodies in transgenic mice expressing the dominant negative TGF\#946;-RII (DNR) gene in CD4+ and CD8+ cells
Journal Articles

Activity and immune cell subset analysis of Interleukin-2 administered to tumor-bearing transgenic mice expressing the dominant negative TGF-beta receptor in CD4+ and CD8+ T lymphocytes (DNR mice).

Stephen Wrzesinski, Mario Sznol, Yisong Wan, Richard Flavell
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 3801.
Published: 01 May 2008
View article titled, Activity and immune cell subset analysis of Interleukin-2 administered to tumor-bearing transgenic mice expressing the dominant negative TGF-beta receptor in CD4+ and CD8+ T lymphocytes (DNR mice).
Journal Articles

Cloretazine™, a novel sulfonylhydrazine alkylating agent, combined with cytarabine is an active regimen in patients with refractory hematologic malignancies

Francis J. Giles, Susan O’Brien, Srdan Verstovsek, Jorge Cortes, Debra Thomas, Stephan Faderl, Alessandra Ferrajoli, Farhad Ravandi-Kashani, Steven Kornblau, Guillermo Garcia-Manero, Ann Cahill, Mario Sznol, Hagop Kantarjian
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 935.
Published: 01 May 2005
View article titled, Cloretazine™, a novel sulfonylhydrazine alkylating agent, combined with cytarabine is an active regimen in patients with refractory hematologic malignancies
Journal Articles

Anti-CD3 Monoclonal Antibody Treatment of Patients with CD3-Negative Tumors: A Phase IA/B Study

Walter J. Urba, Cynthia Ewel, William Kopp, John W. Smith, II, Ronald G. Steis, Jonathan D. Ashwell, Stephen P. Creekmore, Jeffrey Rossio, Mario Sznol, William Sharfman, Robert Fenton, John Janik, Thelma Watson, Joy Beveridge, Dan L. Longo
Journal: Cancer Research
Cancer Res (1992) 52 (9): 2394–2401.
Published: 01 May 1992
View article titled, Anti-CD3 Monoclonal Antibody Treatment of Patients with CD3-Negative Tumors: A Phase IA/B Study
Open the PDF for Anti-CD3 Monoclonal Antibody Treatment of Patients with CD3-Negative Tumors: A Phase IA/B Study in another window
Journal Articles

Interleukin 2 and Lymphokine-activated Killer Cell Therapy: Analysis of a Bolus Interleukin 2 and a Continuous Infusion Interleukin 2 Regimen

Jeffrey W. Clark, John W. Smith, II, Ronald G. Steis, Walter J. Urba, Edward Crum, Robin Miller, John McKnight, JoAnn Beman, Henry C. Stevenson, Stephen Creekmore, Michael Stewart, Kevin Conlon, Mario Sznol, Peter Kremers, Paul Cohen, Dan L. Longo
Journal: Cancer Research
Cancer Res (1990) 50 (22): 7343–7350.
Published: 01 November 1990
View article titled, Interleukin 2 and Lymphokine-activated Killer Cell Therapy: Analysis of a Bolus Interleukin 2 and a Continuous Infusion Interleukin 2 Regimen
Open the PDF for Interleukin 2 and Lymphokine-activated Killer Cell Therapy: Analysis of a Bolus Interleukin 2 and a Continuous Infusion Interleukin 2 Regimen in another window
Journal Articles

Phase I and Immunomodulatory Study of a Muramyl Peptide, Muramyl Tripeptide Phosphatidylethanolamine

Walter J. Urba, Lynn C. Hartmann, Dan L. Longo, Ronald G. Steis, John W. Smith, II, Igal Kedar, Stephen Creekmore, Mario Sznol, Kevin Conlon, William C. Kopp, Christoph Huber, Manfred Herold, W. Gregory Alvord, Sandra Snow, Jeffrey W. Clark
Journal: Cancer Research
Cancer Res (1990) 50 (10): 2979–2986.
Published: 01 May 1990
View article titled, Phase I and Immunomodulatory Study of a Muramyl Peptide, Muramyl Tripeptide Phosphatidylethanolamine
Open the PDF for Phase I and Immunomodulatory Study of a Muramyl Peptide, Muramyl Tripeptide Phosphatidylethanolamine in another window